top of page

Canine Oncology Treatment Data
Intratumoral (IT) administration of MIE-201 has demonstrated durable and systemic antitumor activity as a single agent and in combination treatment regimens in studies of canine patients with several different cancers.
Antitumor Activity Observed in Naturally Occurring Canine Cancers
>25 dogs treated to date
Single Agent
-
Mammary cancer (MC) (unpublished)
-
Inflammatory mammary cancer (IMC)
Combination Treatment
-
Melanoma with radiation
-
IMC with chemotherapy
-
Carcinoma with radiation + hyperthermia

Overall Observations
• Single agent anti-tumor activity
• Combination treatment activity
• Increased recruitment of immune cells into tumors
• Systemic anti-tumor responses (abscopal effect observed)
• Positive safety profile
Canine Data: Broad and Consistent Immune Activation and Antitumor Effects
If you are a veterinarian interested in learning more about MIE-201 and our plans for its continued development for the treatment of canine cancers, please contact us.
bottom of page